Form 4 for KURA Kura Oncology, Inc.
Accepted 2025-08-14 00:00:00 ET · period of report 2025-08-12 · accession 0000950170-25-108844 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-14 | 2025-08-12+ | KURA | WILSON TROY EDWARD | Pres, CEO, Dir | P - Purchase | $6.06 | +50.0K | 51.0K | +5,165% | +$303.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-12 | P | A | 36,506 | $5.85 | 37,474 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $5.56 to $5.995. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes 409 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-08-13 | P | A | 13,494 | $6.64 | 50,968 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $6.485 to $6.735. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |